ArticleBMC cancer2022

Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.

Takaya Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.